Aktuelle therapie der myasthenia gravis und der autoimmunen myositiden

  • Schneider-Gold C
  • 4


    Mendeley users who have this article in their library.
  • 1


    Citations of this article.


Here we characterise modern treatment algorithms for myasthenia gravis and Lambert- Eaton myasthenic syndrome, as well as for dermato and polymyositis and introduce the current principles of escalating therapeutic strategies. Besides glucocorticosteroids, azathioprine is still the standard base line treatment which may be substituted by mycophenolate mofetil, cyclosporine A, tacrolimus, methotrexate or cyclophosphamide in the case of intolerance or lack of therapeutic efficacy. Inmyasthenic crisis, plasmapheresis and/ or immunoadsorption and intravenous immunoglobulins are evidence-based treatment options. In severe dermato- and polymyositis, the role of plasmapheresis is less clear, while intravenous immunoglobulins were shown to improve dermatomyositis. Rituximab is emerging as a new therapeutic option for severe myasthenia gravis and dermatomyositis. Treatment strategies for inclusion body myositis are still ebing discussed controversely. (c) Georg Thieme Verlag KG Stuttgart

Author-supplied keywords

  • Lambert-Eaton myasthenic syndrome
  • Myasthenia gravis
  • Myositis
  • Therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Christiane Schneider-Gold

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free